DexCom Inc (DXCM)

NASDAQ
Currency in USD
80.00
-1.01(-1.25%)
Closed·
After Hours
79.70-0.30(-0.37%)
·
DXCM Scorecard
Full Analysis
Management has been aggressively buying back shares
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
79.6182.06
52 wk Range
57.52117.19
Key Statistics
Edit
Prev. Close
81.01
Open
81.6
Day's Range
79.61-82.06
52 wk Range
57.52-117.19
Volume
5.24M
Average Volume (3m)
3.99M
1-Year Change
-31.41%
Book Value / Share
5.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DXCM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
98.59
Upside
+23.23%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

DexCom Inc News & Analysis

Show more

DexCom Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc SWOT Analysis


CGM Market Leade
Explore DexCom's dominant position in continuous glucose monitoring technology, driving innovation and expanding market reach in diabetes management
Financial Resilience
Delve into DexCom's robust financial performance, with $4.15 billion in trailing twelve-month revenue and a strong gross margin of 59.43%
Growth Catalysts
Uncover DexCom's strategic expansion into Type 2 diabetes market and international growth potential, positioning the company for sustained success
Analyst Outlook
Average price target of $99, with analysts projecting potential outperformance and anticipating DexCom to exceed its conservative 2025 revenue guidance
Read full SWOT analysis

DexCom Inc Earnings Call Summary for Q1/2025

  • DexCom Q1 2025 revenue beat expectations at $1.04B, up 14% YoY, driven by strong U.S. sales; EPS slightly missed at $0.32
  • Company announced $750M share repurchase program and launched new products including Stello CGM and 15-day Com G7 system
  • Full-year revenue guidance set at $4.6B, representing 14% growth; gross margin guidance adjusted to approximately 62%
  • Stock rose 3.2% in after-hours trading to $72.51; analysts maintain positive outlook with price targets ranging from $80 to $115
  • CEO highlighted value of products in cost savings; CFO noted opportunities for expanding Type 2 diabetes coverage in 2025
Last Updated: 01/05/2025, 22:48
Read Full Transcript

Compare DXCM to Peers and Sector

Metrics to compare
DXCM
Peers
Sector
Relationship
P/E Ratio
58.6x−4.7x−0.5x
PEG Ratio
−4.40−0.160.00
Price/Book
13.8x3.6x2.6x
Price / LTM Sales
7.6x2.5x3.0x
Upside (Analyst Target)
25.0%99.3%52.4%
Fair Value Upside
Unlock−21.7%8.7%Unlock

Analyst Ratings

24 Buy
3 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 98.59
(+23.23% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
0.32 / 0.33
Revenue / Forecast
1.04B / 1.02B
EPS Revisions
Last 90 days

DexCom (DXCM) Income Statement & Profits

People Also Watch

228.35
ADI
-0.57%
509.72
REGN
-0.75%
127.04
BIIB
+0.40%
302.01
UNH
-1.69%
99.85
FTNT
-0.96%

FAQ

What Is the DexCom (DXCM) Share Price Today?

The live DexCom share price today is 80.00.

What Stock Exchange Does DexCom (DXCM) Trade On?

DexCom is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for DexCom?

The stock symbol (also called a 'ticker') for DexCom is "DXCM."

What Is the Current DexCom Market Cap?

As of today, DexCom market capitalisation is 31.37B.

What Is DexCom's (DXCM) Earnings Per Share (TTM)?

The DexCom EPS 1.36 (Trailing Twelve Months).

When Is the Next DexCom Earnings Date?

DexCom's next earnings report will be released on 23 Jul 2025.

Is DXCM a Buy or Sell From a Technical Analyst Perspective?

Based on today's DexCom moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has DexCom Stock Split?

DexCom has split 1 times. (See the DXCM stock split history page for full effective split date and price information.)

How Many Employees Does DexCom Have?

DexCom currently has 10250 employees.

What is the current trading status of DexCom (DXCM)?

As of 22 Jun 2025, DexCom (DXCM) is trading at a price of 80.00, with a previous close of 81.01. The stock has fluctuated within a day range of 79.61 to 82.06, while its 52-week range spans from 57.52 to 117.19.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.